It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. [Operator Instructions]. I will now ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Amid a decade-high surge in drug shortages, the American Medical Association has adopted new policy measures aimed at addressing the crisis.

Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Allurion Third Quarter Earnings Call. All lines have been ...

(Irwin, 11/13) Yahoo Finance: Hims & Hers Launches GLP-1 Tracker In Response To FDA's Shortage Decision Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s ...

Global diabetes rates have doubled over the past 30 years, with many middle- and low-income countries failing to provide ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.